Every day, biotech companies are fighting to make the world a better, healthier, and safer place, and if releasing favorable clinical trial news makes shares jump, then that’s a bonus. Today, this happened after results of the ProQR Therapeutics clinical trial were released.
ProQR Therapeutics N.V. (NASDAQ:PRQR)
The PRQR stock is currently up nearly 70%, making it a Yahoo Finance trending ticker. Is that surprising, though? On Wednesday, the Netherlands-based company provided the masses with data from its phase 1/2 trial, which is testing the QR-110 compound. The company is working toward the compound being used to treat a genetic mutation called LCA10.
The LCA10 genetic mutation can lead to childhood blindness. In the ProQR Therapeutics clinical trial, researchers found that QR-110 led to improvements in the following:
- Mobility course performance tests
Further, over 50% of patients (60%) showed a positive response to the QR-110 drug. This was after three months of treatment.
The PRQR Share Price: September 5th, 2018
According to Yahoo Finance, as of 1:13 p.m. EDT, PRQR is trading at $13.05 on the Nasdaq Exchange, which puts the stock up 64.15%.
Earlier in the trading day, shares rose to more than 70%.
In the first half of next year, PRQR will commence its phase 2/3 trial, which will be extremely pivotal.
If all goes well, the RNA medicines sector could have a new leader. That, or the opposite could happen, and the trial could run into speed bumps, sending the PRQR stock down 60%, rather than up like today. That’s simply pessimism though; so far, so good.
What do you think of the ProQR Therapeutics clinical trial? Game-changer? Is the nearly 70% increase deserved?
If you’re a biotech investor, this is definitely a company and clinical trial you’re going to want to watch over. 2019 will be here before you know it, and that means the phase 2/3 trial will be too.
Featured Image: Twitter